GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (OTCPK:TEVJF) » Definitions » Debt-to-Asset

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Debt-to-Asset : 0.46 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Teva Pharmaceutical Industries Debt-to-Asset?

Teva Pharmaceutical Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,672 Mil. Teva Pharmaceutical Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18,481 Mil. Teva Pharmaceutical Industries's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $43,479 Mil. Teva Pharmaceutical Industries's debt to asset for the quarter that ended in Dec. 2023 was 0.46.

Teva Pharmaceutical Industries Debt-to-Asset Historical Data

The historical data trend for Teva Pharmaceutical Industries's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Debt-to-Asset Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.52 0.49 0.49 0.46

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.48 0.49 0.48 0.46

Competitive Comparison of Teva Pharmaceutical Industries's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Debt-to-Asset falls into.


Teva Pharmaceutical Industries Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Teva Pharmaceutical Industries's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1672 + 18481) / 43479
=0.46

Teva Pharmaceutical Industries's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1672 + 18481) / 43479
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries  (OTCPK:TEVJF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Teva Pharmaceutical Industries Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (OTCPK:TEVJF) » Definitions » Debt-to-Asset
Comparable Companies
XTAE:KMDA XTAE:REKA XTAE:TKUN XTAE:PNAX XTAE:NXTG XTAE:CNTC XTAE:PMCN-M ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523
Traded in Other Exchanges
TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEVA:Austria
Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Website
https://www.tevapharm.com
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.